Table 1 Baseline characteristics and comparison of immunogenicity in each group according to measles immunity status
Group 1 (natural immunity) | Group 2 (vaccine-induced immunity) | Group 3 (vaccine failure) | P value | |
|---|---|---|---|---|
Age | 52 ± 1 (51–53) | 41 ± 5 (38–46) | 32 ± 6 (27–35) | < 0.001 |
Male | 15 (37.5) | 5 (12.5) | 11 (27.5) | 0.038 |
Baseline | ||||
Anti-measles IgG, AU/mL | 300 (201–300) | 283 (130–300) | 7 (0.6–11) | < 0.001 |
1 month after MMR vaccination | ||||
Anti-measles IgG, AU/mL | NA | NA | 165 (83–300) | 0.047* |
Neutralizing Ab, mIU/mL | 944 (482–1249) | 405 (301–704) | 482 (272–780) | 0.001 |
Above medium (> 121) | 39/40 (97.5) | 38/40 (95) | 40/40 (100) | 1.00 |
High (> 900) | 23/40 (57.5) | 7/40 (17.5) | 7/40 (7.5) | < 0.001 |
Avidity (%) | 63 (58–68) | 70 (67–74) | 68 (61–73) | 0.003 |
High avidity (55%) | 31/40 (77.5) | 36/40 (90) | 31/35 (88.6) | 0.030 |
6 months after MMR vaccination | ||||
Neutralizing Ab, mIU/mL | 826 (441–1279) | 401 (287–653) | 470 (280–806) | 0.011 |
Above medium (> 121) | 36/37 (97.3) | 36/40 (90) | 28/28 (100) | 0.035 |
High (> 900) | 17/37 (45.9) | 6/40 (15) | 5/28 (17.9) | < 0.001 |
Avidity (%) | 65 (57–75) | 71 (66–75) | 61 (58–69) | 0.005 |
High avidity (55%) | 30/37 (81) | 36/38 (94.8) | 23/28 (82.1) | 0.010 |